Evaluation of differential effects of metformin treatment in obese children according to pubertal stage and genetic variations: Study protocol for a randomized controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Pastor Villaescusa, Belén ^a   Caballero Villarraso, Javier ^b   Cañete, M Dolores ^c   Hoyos, Raúl ^d   Maldonado, José ^d   Bueno, Gloria ^e,h   Leis, Rosaura ^f,h   GilAngel ^a,h,i   Cañete, Ramón ^g,h   Aguilera, Concepción M ^a,h,i  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^f UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h Instituto de Salud Carlos III   (Spain)

ⁱ Instituto de Investigación Biosanitaria ibs   (Spain)

Author keywords

Children; Lifestyle intervention; Metformin; Microbiota; Obesity; Polymorphisms; Puberty

Indexed keywords

BIOLOGICAL MARKER; METFORMIN; PLACEBO; ANTIDIABETIC AGENT;

ADOLESCENT; ADVERSE DRUG REACTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHILD; CHILDHOOD OBESITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; GENETIC VARIATION; HUMAN; INFLAMMATION; INTESTINE FLORA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRACTICE GUIDELINE; PREPUBERTY; PROSPECTIVE STUDY; PUBERTY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; SEX; SPAIN; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT CHANGE; AGE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GASTROINTESTINAL TRACT; GENETIC POLYMORPHISM; HEALTHY LIFESTYLE; METHODOLOGY; MICROBIOLOGY; PATHOPHYSIOLOGY; PHARMACOGENETIC VARIANT; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BIOMARKERS; BODY MASS INDEX; CHILD; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HEALTHY LIFESTYLE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; PEDIATRIC OBESITY; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PUBERTY; RESEARCH DESIGN; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84978834509     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1403-4     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention (CDC). Self-reported influenza-like illness during the 2009 H1N1 influenza pandemic-United States, September 2009-March 2010. MMWR Morb Mortal Wkly Rep. 2011;60:37-41.
2. Freedman DS, Dietz WH, Srinivasan SR, Berenson GS. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics. 1999;103(6 Pt 1):1175-82.
3. Reilly JJ, Methven E, McDowell ZC, Hacking B, Alexander D, Stewart L, Kelnar CJH. Health consequences of obesity. Arch Dis Child. 2003;88:748-52.
4. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362-74.
5. Cañete R, Gil-Campos M, Aguilera CM, Gil A. Development of insulin resistance and its relation to diet in the obese child. Eur J Nutr. 2007;181-187.
6. Rogovik AL, Chanoine J-P, Goldman RD. Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity. Drugs. 2010;70:335-46.
7. Golay A. Metformin and body weight. Int J Obes (Lond). 2008;32:61-72.
8. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074-80.
9. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008;152:817-22.
10. Burgert TS, Duran EJ, Goldberg-gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567-76.
11. Wilson DM, Abrams SH, Aye T, Lee PD, Lenders C, Lustig RH, Osganian SV, Feldman HA, Glaser Pediatric Research Network Obesity Study G. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med. 2010;164:116-23.
12. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457-61.
13. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21:339-48.
14. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jiménez E, Muñoz-Noriega N, García-Morales LM, Leaños-Pérez C, Figueroa-Barrón M, Sánchez-Fierros D, Reyes-García JG. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab. 2012;41-49.
15. Gómez-Díaz RA, Talavera JO, Pool EC, Ortiz-Navarrete FV, Solórzano-Santos F, Mondragón-González R, Valladares-Salgado A, Cruz M, Aguilar-Salinas CA, Wacher NH. Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. Metabolism. 2012;61:1247-55.
16. Mauras N, Delgiorno C, Hossain J, Bird K, Killen K, Merinbaum D, Weltman A, Damaso L, Balagopal P. Metformin use in children with obesity and normal glucose tolerance-effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25:33-40.
17. Rynders C, Weltman A. Lifestyle intervention improves fitness independent of metformin in obese adolescents. Med Sci Sports Exerc. 2012;44:786-92.
18. Kendall D, Vail A, Amin R, Barrett T, Dimitri P, Ivison F, Kibirige M, Mathew V, Matyka K, McGovern A, Stirling H, Tetlow L, Wales J, Wright N, Clayton P, Hall C. Metformin in obese children and adolescents: the MOCA Trial. J Clin Endocrinol Metab. 2013;98:322-9.
19. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168:178-84.
20. Sanz Y, Olivares M, Moya-Pérez Á, Agostoni C. Understanding the role of gut microbiome in metabolic disease risk. Pediatr Res. 2014;77:236-44.
21. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, Arumugam M, Kristiansen K, Yvonne Voigt A, Vestergaard H, Hercog R, Igor Costea P, Roat Kultima J, Li J, Jørgensen T, Levenez F, Dore J, MetaHIT consortium, Bjørn Nielsen H, Brunak S, Raes J, Hansen T, Wang J, Dusko Ehrlich S, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262-6.
22. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 2009;9:242-7.
23. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58:745-9.
24. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010;20:38-44.
25. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child. 1976;51:170-9.
26. Vyncke K, Cruz Fernandez E, Fajó-Pascual M, Cuenca-García M, De Keyzer W, Gonzalez-Gross M, et al. Validation of the Diet Quality Index for Adolescents by comparison with biomarkers, nutrient and food intakes: the HELENA study. Br J Nutr. 2012;25:1-12. Epub 30 Oct 2012.
27. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-95.
28. Moreno LA, González-Gross M, Kersting M, Molnár D, de Henauw S, Beghin L, Sjöström M, Hagströmer M, Manios Y, Gilbert CC, Ortega FB, Dallongeville J, Arcella D, Wärnberg J, Hallberg M, Fredriksson H, Maes L, Widhalm K, Kafatos AG, Marcos A. Assessing, understanding and modifying nutritional status, eating habits and physical activity in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) Study. Public Health Nutr. 2008;11:288-99.
29. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320:1240-3.
30. Rolland-Cachera MF, Sempé M, Guilloud-Bataille M, Patois E, Péquignot-Guggenbuhl F, Fautrad V. Adiposity indices in children. Am J Clin Nutr. 1982;36:178-84.
31. Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández-Ramos C, Lizárraga A, Lorenzo A, Madariaga L, Rica I, Ruiz I, Sáchez E, Santamaría E, Serrano JM, Zabala A, Zurimend B, Hernández M. Curvas y tablas de crecimiento, Instituto de Investigación sobre Crecimiento y Desarrollo. Fund Faustino Orbegozo Madrid Editor Garsi. 2004.
32. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.
33. Wiegand S, L'Allemand D, Hübel H, Krude H, Bürmann M, Martus P, Grüters A, Holl RW. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol. 2010;163:585-92.
34. Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011;60:477-85.
35. Chen S, Zhou J, Xi M, Jia Y, Wong Y, Zhao J, Ding L, Zhang J, Wen A. Pharmacogenetic variation and metformin response. Curr Drug Metab. 2013;14:1070-82.
36. Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, Sahu A, Bass E, Kao WHL, Clark JM. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37:876-86.